Literature DB >> 26885454

Increased NUCKS expression is a risk factor for poor prognosis and recurrence in endometrial cancer.

Tianbo Liu1, Shu Tan1, Ye Xu1, Fanling Meng1, Chang Yang1, Ge Lou1.   

Abstract

Nuclear ubiquitous casein and cyclin-dependent kinases substrate (NUCKS) was reported to function as a potential biomarker in various tumors. Thus, we aimed to explore the expression of NUCKS in endometrial cancer (EC) and its clinical significance using quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC). qRT-PCR results showed that NUCKS mRNA expression gradually elevated from normal endometrium to atypical endometrial hyperplasia, and to EC (P < 0.05 between each group). NUCKS overexpression was strongly associated with FIGO stage (P = 0.002), histologic grade (P = 0.029), lympho-vascular space involvement (P = 0.014), lymph node metastasis (P = 0.019), and recurrence (P < 0.001). Cox multivariate analysis revealed that NUCKS overexpression was an independent factor for overall survival and recurrence-free survival (P < 0.001 for both). Multivariate logistic regression suggested that recurrence was independently correlated with NUCKS overexpresion (P = 0.039), FIGO stage (P = 0.002), and lymph node metastasis (P = 0.002). In summary, NUCKS overexpression may function as a potential biomarker for prognosis especially for recurrence in ECs.

Entities:  

Keywords:  Endometrial cancer; nuclear ubiquitous casein and cyclin-dependent kinases substrate (NUCKS); prognosis; recurrence

Year:  2015        PMID: 26885454      PMCID: PMC4731639     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  29 in total

1.  Identification and confirmation of a module of coexpressed genes.

Authors:  H Garrett R Thompson; Joseph W Harris; Barbara J Wold; Stephen R Quake; James P Brody
Journal:  Genome Res       Date:  2002-10       Impact factor: 9.043

2.  Follow-up practice in endometrial cancer and the association with patient and hospital characteristics: a study from the population-based PROFILES registry.

Authors:  Kim A H Nicolaije; Nicole P M Ezendam; M Caroline Vos; Dorry Boll; Johanna M A Pijnenborg; Roy F P M Kruitwagen; Marnix L M Lybeert; Lonneke V van de Poll-Franse
Journal:  Gynecol Oncol       Date:  2013-02-19       Impact factor: 5.482

3.  Phosphorylation of the high-mobility-group-like protein P1 by casein kinase-2.

Authors:  G M Maelandsmo; A C Ostvold; S G Laland
Journal:  Eur J Biochem       Date:  1989-10-01

4.  Immunocytochemical studies on the nuclear ubiquitous casein and cyclin-dependent kinases substrate following 5-aminolevulinicacid-mediated photodynamic therapy on MCF-7 cells.

Authors:  Katarzyna Hotowy; Marta Woźniak; Kamila Duś; Elżbieta Czapińska; Beata Osiecka; Małgorzata Krzystek-Korpacka; Andrzej Bronowicz; Jacek Wiśniewski; Andrzej Gamian; Grzegorz Terlecki; Piotr Ziółkowski
Journal:  Photodiagnosis Photodyn Ther       Date:  2013-04-18       Impact factor: 3.631

5.  NUCKS1 overexpression is a novel biomarker for recurrence-free survival in cervical squamous cell carcinoma.

Authors:  Lina Gu; Bairong Xia; Lili Zhong; Yuan Ma; Lei Liu; Liping Yang; Ge Lou
Journal:  Tumour Biol       Date:  2014-05-13

6.  HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer.

Authors:  Gerhild Fabjani; Dan Tong; Andrea Wolf; Sebastian Roka; Sepp Leodolter; Paul Hoecker; Michael Bernhard Fischer; Raimund Jakesz; Robert Zeillinger
Journal:  Oncol Rep       Date:  2005-09       Impact factor: 3.906

7.  Chromosomal changes in high- and low-invasive mouse lung adenocarcinoma cell strains derived from early passage mouse lung adenocarcinoma cell strains.

Authors:  Linda M Sargent; Mang X Ensell; Anne-Carine Ostvold; Kimberly T Baldwin; Michael L Kashon; David T Lowry; Jamie R Senft; Amy M Jefferson; Robert C Johnson; Zhi Li; Frederick L Tyson; Steven H Reynolds
Journal:  Toxicol Appl Pharmacol       Date:  2008-02-08       Impact factor: 4.219

8.  Efficacy of routine follow-up in patients with recurrent uterine cancer.

Authors:  Christopher J Smith; Monique Heeren; James L Nicklin; Lewis C Perrin; Russell Land; Alex J Crandon; Andreas Obermair
Journal:  Gynecol Oncol       Date:  2007-07-25       Impact factor: 5.482

9.  Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths.

Authors:  Stefanie M Ueda; Daniel S Kapp; Michael K Cheung; Jacob Y Shin; Kathryn Osann; Amreen Husain; Nelson N Teng; Jonathan S Berek; John K Chan
Journal:  Am J Obstet Gynecol       Date:  2008-02       Impact factor: 8.661

10.  NUCKS1, a novel Tat coactivator, plays a crucial role in HIV-1 replication by increasing Tat-mediated viral transcription on the HIV-1 LTR promoter.

Authors:  Hye-Young Kim; Byeong-Sun Choi; Sung Soon Kim; Tae-Young Roh; Jihwan Park; Cheol-Hee Yoon
Journal:  Retrovirology       Date:  2014-08-13       Impact factor: 4.602

View more
  4 in total

1.  The prognostic value of D-dimer levels in endometrial cancer patients treated with intensity-modulated radiation therapy.

Authors:  Xiaojing Yang; Hanru Ren; Yi Sun; Lihua Zhang; Xinmiao Yang; Hongling Li; Yuhui Shao; Jie Fu
Journal:  Oncotarget       Date:  2017-04-11

2.  The NUCKS1-SKP2-p21/p27 axis controls S phase entry.

Authors:  Samuel Hume; Claudia P Grou; Pauline Lascaux; Vincenzo D'Angiolella; Arnaud J Legrand; Kristijan Ramadan; Grigory L Dianov
Journal:  Nat Commun       Date:  2021-11-29       Impact factor: 14.919

3.  Nucks1 synergizes with Trp53 to promote radiation lymphomagenesis in mice.

Authors:  Yangbo Yue; Stanley G Leung; Yueyong Liu; Yurong Huang; Kirsten Grundt; Anne-Carine Østvold; Kuang-Yu Jen; David Schild; Jian-Hua Mao; Claudia Wiese
Journal:  Oncotarget       Date:  2016-09-20

Review 4.  Roles of NUCKS1 in Diseases: Susceptibility, Potential Biomarker, and Regulatory Mechanisms.

Authors:  Pengru Huang; Yujie Cai; Bin Zhao; Lili Cui
Journal:  Biomed Res Int       Date:  2018-01-29       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.